慢性sarpogrelate治疗改善了实验糖尿病患者的同情性过活性
Juan Francisco Fernández-González1, José Ángel García-Pedraza1, Anaïs Clara Terol-Úbeda1
1Laboratorio de Farmacología, Departamento de Fisiología y Farmacología, Facultad de Farmacia, Universidad de Salamanca, Salamanca 37007, Spain; Instituto de Investigación Biomédica de Salamanca (IBSAL), Paseo San Vicente 58-182, Salamanca 37007, Spain.
糖尿病病是一种主要的健康问题. 这项研究表明,用sarpogrelate阻断5-hydroxytryptamine (5-HT) 2受体可以减少糖尿病大鼠的损伤和交感神经活动.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病脏病和神经病变是全球发病率和死亡率的重要原因.
- 5-基三胺 (5-HT) 影响交感输入和血管律.
- 以前的研究表明,5-HT2受体阻塞可能会减少糖尿病微血管并发症.
研究的目的:
- 为了研究5-HT2受体阻塞是否改善糖尿病大鼠的功能.
- 描述血清素在调节交感神经传递中的作用.
主要方法:
- 在Wistar大鼠中使用aloxan诱导糖尿病.
- 糖尿病大鼠接受了14天的萨波格雷拉酸 (一种5-HT2抗剂) 治疗.
- 评估了功能和同情反应,使用 in situ 自身输液,电刺激和 noradrenaline 给药.
主要成果:
- 萨波格莱治疗减少了交感性过活性,缩和损伤标志物.
- 动脉内5-HT抑制了交感诱导的血管收缩,这种效应由5-HT1D/1F和5-HT7受体激活介导.
- 诺拉丁上腺素诱导的血管收缩不受5-HT激动剂的影响.
结论:
- 在实验糖尿病中,慢性sarpogrelate治疗减少了损伤和缩.
- 这项研究表明,sarpogrelate修改了同情神经传递的血清调节.
- 这种修改涉及通过前节性5-HT1D/1F和5-HT7受体激活的交抑制.
更多相关视频
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
08:21A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Direct Renin Inhibitors
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
